GSK PLC closed 21.47% short of its 52-week high of £18.24, which the company reached on May 16th.

Going forward, PTS and Appspace are providing ongoing service and support, with a team ensuring the systems perform at peak ...

GSK PLC closed 22.73% below its 52-week high of £18.24, which the company reached on May 16th.

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...

A global biopharma is fighting malaria in endemic countries through partnerships that harness R&D, broaden access to ...

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

GSK's Jemperli shows 100% efficacy in 49 MMRd rectal cancer patients, with complete disease elimination after six months' ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainan | GSK has been found guilty of ...

We recently published a list of the 11 Best Undervalued UK Stocks to Buy Right Now. In this article, we are going to take a ...

GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...